2025-05-22 06:01:36 pm | Source: reuters
India`s Sun Pharma posts quarterly profit rise on strong demand for rare disease drugs
Sun Pharmaceutical, India's largest drugmaker by revenue, reported a rise in adjusted quarterly profit on Thursday, driven by strong domestic demand for its drugs to treat rare diseases.
The Mumbai-based firm's consolidated profit before exceptional items and tax rose 24% to 36.16 billion rupees ($420.7 million) in the three months ended March 31.
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or
investment advice. Investments in financial markets are subject to market risks, and past performance is
not indicative of future results. Readers are strongly advised to consult a licensed financial expert or
advisor for tailored advice before making any investment decisions. The data and information presented
in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the
content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
Market Round-up - 12th August 2026 by Motilal Oswal ...
Manufacturing GVA grows at 10.88 pc during FY23-FY26...
FIIs stood as net sellers in equities as per August ...
Karnataka, Israel hold cyber dialogue 2026; join han...
Indian NBFC fintech loan book grows 21.2 pc in June ...
BRICS economies are major engines of global growth: ...
Quote on CPI by Rajeev Sharan, Head ? Criteria, Mode...
Milky Mist IPO: Temasek-backed firm flags Rs 229 cro...
Sensex, Nifty extend losses for 2nd day as firm oil ...
India, Iran central bank chiefs hold talks on closer...
